Myeloma bone disease: from biology findings to treatment approaches

被引：109
作者：
Terpos, Evangelos [1 ]
Ntanasis-Stathopoulos, Ioannis [1 ]
Dimopoulos, Meletios A. [1 ]
机构：
[1] Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece
来源：
BLOOD | 2019年 / 133卷 / 14期
关键词：
DIAGNOSED MULTIPLE-MYELOMA; MARROW STROMAL CELLS; ZOLEDRONIC ACID; RECEPTOR ACTIVATOR; SKELETAL COMPLICATIONS; OSTEOLYTIC LESIONS; CLODRONIC ACID; DOUBLE-BLIND; ACTIVIN-A; DENOSUMAB;
D O I：
10.1182/blood-2018-11-852459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregulate bone turnover and result in bone loss and skeletal-related events. Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations in this constantly evolving field are thoroughly discussed.
引用
收藏
页码：1534 / 1539
页数：6
相关论文
共 71 条
[1]   Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication [J].
An, Gang ;
Acharya, Chirag ;
Feng, Xiaoyan ;
Wen, Kenneth ;
Zhong, Mike ;
Zhang, Li ;
Munshi, Nikhil C. ;
Qiu, Lugui ;
Tai, Yu-Tzu ;
Anderson, Kenneth C. .
BLOOD, 2016, 128 (12) :1590-1603
[2]   WNT signaling in bone homeostasis and disease: from human mutations to treatments [J].
Baron, Roland ;
Kneissel, Michaela .
NATURE MEDICINE, 2013, 19 (02) :179-192
[3]   Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[4]   A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer [J].
Body, JJ ;
Facon, T ;
Coleman, RE ;
Lipton, A ;
Geurs, F ;
Fan, M ;
Holloway, D ;
Peterson, MC ;
Bekker, P .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1221-1228
[5]   10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J].
Bone, Henry G. ;
Wagman, Rachel B. ;
Brandi, Maria L. ;
Brown, Jacques P. ;
Chapurlat, Roland ;
Cummings, Steven R. ;
Czerwinski, Edward ;
Fahrleitner-Pammer, Astrid ;
Kendler, David L. ;
Lippuner, Kurt ;
Reginster, Jean-Yves ;
Roux, Christian ;
Malouf, Jorge ;
Bradley, Michelle N. ;
Daizadeh, Nadia S. ;
Wang, Andrea ;
Dakin, Paula ;
Pannacciulli, Nicola ;
Dempster, David W. ;
Papapoulos, Socrates .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :513-523
[6]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[7]   Osteoblastic niche supports the growth of quiescent multiple myeloma cells [J].
Chen, Zheng ;
Orlowski, Robert Z. ;
Wang, Michael ;
Kwak, Larry ;
McCarty, Nami .
BLOOD, 2014, 123 (14) :2204-2208
[8]   Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes [J].
Colombo, M. ;
Mirandola, L. ;
Platonova, N. ;
Apicella, L. ;
Basile, A. ;
Figueroa, A. J. ;
Cobos, E. ;
Chiriva-Internati, M. ;
Chiaramonte, R. .
LEUKEMIA, 2013, 27 (05) :1009-1018
[9]   Myeloma cells suppress osteoblasts through sclerostin secretion [J].
Colucci, S. ;
Brunetti, G. ;
Oranger, A. ;
Mori, G. ;
Sardone, F. ;
Specchia, G. ;
Rinaldi, E. ;
Curci, P. ;
Liso, V. ;
Passeri, G. ;
Zallone, A. ;
Rizzi, R. ;
Grano, M. .
BLOOD CANCER JOURNAL, 2011, 1 :e27-e27
[10]   Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma - A possible mechanism for its antitumor effect [J].
Corso, A ;
Ferretti, E ;
Lunghi, M ;
Zappasodi, P ;
Mangiacavalli, S ;
De Amici, M ;
Rusconi, C ;
Varettoni, M ;
Lazzarino, M .
CANCER, 2005, 104 (01) :118-125
12345678